Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens myocyte enhancer factor 2A (MEF2A), transcript variant 1
Synonyms:
ADCAD1; mef2; RSRFC4; RSRFC9
Immunogen
A synthetic peptide corresponding to residues in human MEF2A was used as an immunogen.
Buffer
Store at -20 C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
MEF2A (myocyte specific enhancer factor 2) is a transcription factor protein that belongs to MEF2 family, a family of DNA binding regulatory proteins. MEF2 family members (MEF2A, 2B, 2C, and 2D) are highly expressed during dendritic maturation and synapse formation in the brain and are involved in the regulation of development and function of T-cell, muscle cells, and brain cells (1). Highly expressed during synaptogenesis, MEF2A binds to MEF2 element present in the regulatory regions in various muscle specific genes and activates transcription. MEF2A has been implicated in cardiac and skeletal muscle development (2).
Related Pathway
Adipogenesis
TGF Beta Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
